PFE — PFIZER INC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 78003 ·
Last close
$28.52
Market Cap
$162.55B
52W High
$29.21
52W Low
$22.57
ADV30
33,692,825
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,034,000,000 | 10,942,000,000 | 3,537,000,000 | -248,000,000 | 201,131,000,000 | 976,000,000 | 115,639,000,000 |
| Mar 2026 | 14,450,000,000 | 10,902,000,000 | 4,131,000,000 | 2,687,000,000 | 207,618,000,000 | 1,703,000,000 | 117,214,000,000 |
| Dec 2025 | 17,557,000,000 | 12,285,000,000 | 3,475,000,000 | -1,648,000,000 | 208,160,000,000 | 1,142,000,000 | 121,385,000,000 |
| Sep 2025 | 16,654,000,000 | 12,482,000,000 | 4,137,000,000 | 3,541,000,000 | 208,731,000,000 | 1,343,000,000 | 115,635,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,403,000,000
Investing CF
$-5,683,000,000
Financing CF
$-8,399,000,000
CapEx
$-2,416,000,000
Dividends Paid
$-9,785,000,000
Buybacks
—
EPS Diluted TTM
$0.76
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$112,087,000,000
Inventory
$9,945,000,000
Receivables
$16,192,000,000
ST Investments
$10,722,000,000
EBIT TTM
$6,907,000,000
Pretax Income TTM
$4,209,000,000
Interest Exp TTM
$2,698,000,000
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$63,695,998,976
EBITDA
$25,383,000,064
Free Cash Flow
$12,485,624,832
Enterprise Value
$210,072,944,640
Total Cash
$11,704,000,512
Total Debt
$63,480,000,512
Shares Out
5,699,673,589
Trailing EPS
$0.76
Book Value
$14.95
ROE
5.0%
ROA
5.8%
Div Yield
6.20%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,579,000,000 | 17,407,000,000 | 7,771,000,000 | 208,160,000,000 | 121,385,000,000 | 86,476,000,000 | 11,704,000,000 |
| Dec 2024 | 63,627,000,000 | 14,938,000,000 | 8,031,000,000 | 213,396,000,000 | 124,899,000,000 | 88,203,000,000 | 12,744,000,000 |
| Dec 2023 | 59,554,000,000 | 4,417,000,000 | 2,119,000,000 | 226,501,000,000 | 137,213,000,000 | 89,014,000,000 | 8,700,000,000 |
| Dec 2022 | 101,175,000,000 | 38,117,000,000 | 31,372,000,000 | 197,205,000,000 | 101,289,000,000 | 95,661,000,000 | 29,267,000,000 |
TTM Snapshot
Revenues TTM
$67,546,000,000
NetIncome TTM
$13,658,000,000
OpCashFlow TTM
$0
Assets (Latest)
$208,160,000,000
Forward EPS
$2.90
Max Pain — expiry 2026-10-09 (volume-derived — Yahoo OI feed degraded)
max pain strike: $28.50 · spot: $28.52 · call volume: 8,101 · put volume: 3,951
Expected Move to 2026-10-09:
±$0.78
(2.73%) —
implied range
$27.74 –
$29.30
· ATM straddle on $28.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | $171.01B | $98.83 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.51B | $522.81 | — |
| NONOF | NOVO NORDISK A S | $127.58B | $38.15 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $127.47B | $62.40 | — |
| NVO | NOVO NORDISK A S | $126.77B | $37.91 | — |
News headlines (Yahoo Finance, 1h cache)
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
2026-10-01 06:30 · Yahoo
PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer
2026-09-30 15:34 · Yahoo
Are You Overpaying For Pfizer Stock Versus Its Rivals?
2026-09-30 15:29 · Yahoo
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
2026-09-30 13:40 · Yahoo
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap?
2026-09-29 20:20 · Yahoo
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now
2026-09-29 17:20 · Yahoo
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
2026-09-29 13:14 · Yahoo
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
2026-09-29 11:00 · Yahoo
Invivyd’s Covid-directed mAb hits Phase III safety goals
2026-09-30 16:19 · Yahoo
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
2026-09-29 09:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.